hVIVO plc Exercise of Share Options (5785O)

TIDMHVO

RNS Number : 5785O

hVIVO plc

02 October 2019

HVIVO plc

("hVIVO" or the "Company")

Exercise of Share Options

London, UK, 2 October 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, following the exercise of employee share options by ex-employees, application has been made to AIM for the admission of 89,482 new ordinary shares of 5 pence each (the "New Ordinary Shares"). Admission to trading on AIM of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 8 October 2019.

Following Admission, the total number of ordinary shares with voting rights in issue will be 83,209,902 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

For further information please contact:

 
 hVIVO plc 
 Anesh Patel (Interim Finance Director & Company Secretary)    [phone] 
 Fleur Wood (EVP, Investor Relations & Communications) 
 Numis Securities Limited                                       [phone] 
 Freddie Barnfield / Huw Jeremy (Nominated Adviser) 
 James Black (Corporate Broking) 
 
 FTI Consulting 
 Simon Conway / Victoria Foster Mitchell                       [phone] 
 

Notes to Editors:

hVIVO is an industry leading clinical development services business supporting product development for customers developing antivirals, vaccines and respiratory therapeutics. Leveraging human disease models in human rhinovirus (HRV), RSV, Influenza (Flu) Asthma and chronic obstructive pulmonary disease (COPD), the hVIVO platform illuminates the entire disease cycle in people from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted 56 clinical studies and inoculated over 2900 volunteers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

ALSQLLFBKBFBFBB

(END) Dow Jones Newswires

October 02, 2019 12:03 ET (16:03 GMT)